Anti-Human PTK7/CCK-4 Reference Antibody (Cofetuzumab, RUO)

Description: Cofetuzumab (BS10455) is a research-grade recombinant antibody targeting Protein-tyrosine kinase 7. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1.11mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Protein-tyrosinekinase7,Inactivetyrosine-proteinkinase7,CCK4,PTK7,Coloncarcinomakinase4,Tyrosine-proteinkinase-like7,CCK-4,Pseudotyrosinekinasereceptor7
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: PF-06523435,hu24,Anti-PTK7ADC,PF-06647020,PTK7-ADC,CAS:1869928-62-0
Background: Inactive tyrosine-protein kinase 7 (PTK7/CCK-4) is a ~118 kDa protein. Inactive tyrosine kinase involved in Wnt signaling pathway. Component of both the non-canonical (also known as the Wnt/planar cell polarity signaling) and the canonical Wnt signaling pathway. Functions in cell adhesion, cell migration, cell polarity, proliferation, actin cytoskeleton reorganization and apoptosis. Has a role in embryogenesis, epithelial tissue organization and angiogenesis.
Note: For research use only. Not suitable for clinical or therapeutic use.